MORRIS PLAINS, N.J., May 5, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that IBC Pharmaceuticals, Inc., a majority-owned subsidiary (IBC), has received notice that its patent application for “Multivalent immunoglobulin-based bioactive assemblies” will issue as U.S. patent no. 7,527,787 today.
